Actively Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-05-11
86
Participants Needed
25
Research Sites
578 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
CONDITIONS
Official Title
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with confirmed advanced, metastatic breast cancer or other solid tumors who have no effective standard therapies left or cannot tolerate them (Part 1A).
- Participants with advanced breast cancer with 1 to 3 prior systemic therapy lines in the metastatic setting, with no more than 2 lines of chemotherapy (Parts 1B and 2A).
- Participants with advanced breast cancer in areas without approved or available CDK4/6 inhibitors as first-line treatment, who have not received CDK4/6 inhibitors or systemic treatment for advanced disease (Parts 2B and 2C).
- Participants with breast cancer must have confirmed advanced breast cancer per ASCO/CAP guidelines.
- Female participants with metastatic breast cancer must be postmenopausal or receiving ovarian function suppression treatment.
- Measurable disease by RECIST v 1.1 criteria.
- Stable ECOG Performance Status of 0 or 1.
- Adequate organ function.
You will not qualify if you...
- Prior treatment with KAT6A/B or KAT7 inhibitors or degraders.
- Active leptomeningeal disease or uncontrolled, untreated brain metastases.
- Any other malignancy within 3 years before screening except the cancer under study or treated local recurrence unlikely to need intervention during the study.
- Additional protocol-defined criteria may apply.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 25 locations
1
University of Alabama At Birmingham Hospital
Birmingham, Alabama, United States, 35294-0004
Actively Recruiting
2
Yale Cancer Center
New Haven, Connecticut, United States, 06510
Actively Recruiting
3
Washington University in St Louis
St Louis, Missouri, United States, 63110-1010
Actively Recruiting
4
Next Oncology Austin
Austin, Texas, United States, 78758
Actively Recruiting
5
The University of Texas Md Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Actively Recruiting
6
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia, NSW 2148
Actively Recruiting
7
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia, NSW 2050
Actively Recruiting
8
Cancer Research South Australia
Adelaide, South Australia, Australia, SA 5000
Actively Recruiting
9
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia, VIC 3000
Actively Recruiting
10
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
11
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
12
Sun Yat Sen University Cancer Center Huangpu Branch
Guangzhou, Guangdong, China, 510555
Actively Recruiting
13
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150000
Actively Recruiting
14
Jiangsu Province Hospital Longjiang Branch
Nanjing, Jiangsu, China, 210036
Actively Recruiting
15
Fudan University Shanghai Cancer Centerpudong
Shanghai, Shanghai Municipality, China, 201321
Actively Recruiting
16
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
17
Istituto Europeo Di Oncologia
Milan, Italy, 20141
Actively Recruiting
18
Istituto Nazionale Tumori Fondazione G Pascale
Naples, Italy, 80131
Actively Recruiting
19
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy, 00168
Actively Recruiting
20
Istituto Clinico Humanitas
Rozzano, Italy, 20089
Actively Recruiting
21
Hospital Universitario Vall Dhebron
Barcelona, Spain, 08035
Actively Recruiting
22
Next Oncology Barcelona
Barcelona, Spain, 8023
Actively Recruiting
23
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
24
Hospital Clinico San Carlos
Madrid, Spain, 28240
Actively Recruiting
25
Hospital Universitario Virgen de La Victoria
Málaga, Spain, 29010
Actively Recruiting
Research Team
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here